Brexit: Insulin Stockpiles are built up

Although all parties involved are looking for a positive outcome of the current negotiations, a so called "hard Brexit" - a scenario in which the U.K. leaves the EU without a full agreement - is possible. This will cause problems in many areas. Preparations are being made in order to deal with it.

According the article "UK's biggest insulin manufacturer building up four-month stockpile in case of no-deal Brexit" in the Independent, about 50% of the insulin needed in the U.K to treat diabetic patients is manufactured by the Danish company NovoNordisk. The company now said that they will build up a stockpile until January 2019 to make sure these diabetic patients will get their medications in the event of a no-deal Brexit. The plan is to have a stockpile lasting for four months. Also the French company Sanofi promised to build up an insulin stockpile (for 14 weeks). The U.K. government has asked companies to build up a six-week stockpile of medications against the consequences of hard Brexit.

Go back


Stay informed with the GMP Newsletters from ECA

GMP Newsletter

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, please click here.